The IMMUcan project has successfully reached a major milestone by enrolling 1500 patients. We extend our gratitude to the SPECTA community of dedicated clinicians and patients for their invaluable contributions to this achievement.

The success of IMMUcan can be attributed to the prospective recruitment of patients through the cutting-edge SPECTA platform, coupled with fruitful collaborations with external trials such as EORTC-1559 Upstream, Institut Jules Bordet-Synergy, and UZ Leuven-Dutrelasco.

The enrollment of such a substantial number of patients is of utmost importance to us, as it propels our mission to unravel the intricate dynamics between the immune system and cancer cells at cellular and molecular level. Through the meticulous analysis of clinical data and samples obtained from patients with colorectal, lung, head and neck, breast, gastric, and renal cancers, we are empowered to construct a comprehensive understanding of the tumour microenvironment and its impact of various treatments.

Interested to learn more about IMMUcan? Visit the IMMUcan website.